Table 5.
Strain | Treatment | BV (mm3)a
|
TV (mm3)b
|
BV/TV (%)c
|
|||
---|---|---|---|---|---|---|---|
Average | P value | Average | P value | Average | P value | ||
B6 | Control | 0.149 ± 0.009 | 0.794 | 2.03 ± 0.06 | 0.789 | 6.6 ± 0.4 | 0.170 |
Rosi | 0.153 ± 0.008 | 2.05 ± 0.05 | 7.4 ± 0.3 | ||||
C3H | Control | 0.641 ± 0.024 | 0.075 | 1.45 ± 0.04 | 0.004 | 44.2 ± 1.6 | 0.001 |
Rosi | 0.573 ± 0.027 | 1.65 ± 0.04 | 35.1 ± 1.7 | ||||
DBA | Control | 0.085 ± 0.007 | 0.279 | 1.57 ± 0.02 | 0.001 | 5.3 ± 0.4 | 0.649 |
Rosi | 0.097 ± 0.007 | 1.72 ± 0.02 | 5.6 ± 0.4 | ||||
A/J | Control | 0.175 ± 0.023 | 0.834 | 1.72 ± 0.03 | 0.010 | 10.3 ± 1.1 | 0.361 |
Rosi | 0.167 ± 0.023 | 1.85 ± 0.03 | 8.8 ± 1.1 | ||||
Strain × Rosi | 0.2547 | 0.0255 | < 0.0001 |
Rosi, Rosiglitazone.
Femur length was a significant covariate for DBA/2J only.
Body weight was a significant covariate for C3H/HeJ and DBA/2J. Femur length was also a significant covariate for C3H/HeJ.
Body weight was a significant covariate for C57BL/6J and A/J. The interaction term of body weight × treatment was also a significant covariate for C57BL/6J. Femur length was a significant covariate for DBA/2J only.